A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

British Journal of Haematology

Volumn 100, Issue 2, 1998, Pages 317-325

  McCloskey, E V ^a   Maclennan, I C M ^a   Drayson, M T ^a   Chapman, C ^a   Dunn, J ^a   Kanis, J A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone pain; Clodronate; Fractures; Hypercalcaemia; Myeloma; Survival

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; BACKACHE; BONE DISEASE; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; ANALGESICS, NON-NARCOTIC; BONE DISEASES; CALCIUM; CLODRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; HYPOCALCEMIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PAIN; TREATMENT OUTCOME;

EID: 0031911183     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00567.x     Document Type: Article

References (32)

1. Adami, S. & Mian, M. (1989) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Here/it Results in Cancer Research, Bisphosphonates and Tumour Osteolysis, 116, 67-72.
2. Anderson, K.M., Rubenstein, M. & Sky-Peck. H. (1982) Mithramycin impairs the release of 45Ca from bone induced by prostaglandin E2 or multiple myeloma sera: implications for a novel means of local tumour control. Oncology 39, 72-77.
3. Bataille. R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
4. Belch, A.R., Bergsagel, D.E.. \Vilson, K., O'Reilly. S.. Wilson, J., Sutton, D., Pater, J., Johnstone, D. & Zee. B. (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology. 9, 1397-1402.
5. Berenson, J.R., Lichenstein, A., Porter, L, Dimopolous, M.A., Bordani, R., George, S., Lipton, A., Keller, A., Ballester, 0.. Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Hefferman, M.. Seaman, J. & Knight. R.D. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488493.
6. Black, K., Mundy. G.R. & Garrett, I.R. (1990) Interleukin-6 causes hypercalcaemia in vivo, and enhances the bone resorbing potency of interleukin-l and tumor necrosis factor by two orders of magnitude in vitro. Journal of Bone Mineralization, 5, 787.
7. Boyce, B.E, Fogelman, I., Ralston, S., Smith. L.. Johnston, E. & Boyle, I.T. (1984) Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet, i, 821-824.
8. Dixon, W., Brown, M. & Engleman, L. (1985) BMDP Statistical Software Manual, 5th edn. University of California Press, Berkeley.
9. Elomaa, I., Blomqvist, C., Porkka, L., Kairento, A.L., Seiander, K., Lamberg-AHardt. C. & Holstrom, T. (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone métastases, lancet, i, 146-148.
10. Ernst. D.S., MacDonald, R.N., Paterson, A.H.G., Jensen, J. & Bruera, E. (1992) A double-blind cross-over trial of IV clodronate in metastatic bone pain. Journal of Pain and Symptom Management, 7, 4-11.
11. Fleisch, H. (1995) Bisphosphonates in Bone Disease: from the Laboratory to the Patient, 2nd edn. The Parthenon Publishing Group, London.
12. Freidlander, G.E.. Tross, R.B., Goganis, A.C., Kirkwood. J.M. & Baron, R. (1984) Effects of chemotherapeutic agents on bone. I. Shortterm methotrexate and doxorubicin (adriamycin) treatment in a rat model. Journal of Bone and Joint Surgery A, 66, 602-607.
13. Garrett, I.R.. Durie, B.G.M., Nedwin, G.E., Gillespie, A., Bringman, T., Sabatini, M., Bertolini, D.R. & Mundy, G.R. (1987) Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. Ne\v England Journal of Medicine, 317, 526-532.
14. Kanis, J.A. & McCloskey, E.V. (1990) The use of clodronate in disorders of calcium and skeletal metabolism. Calcium Metabolism: Programme Basic Clinical Pharmacology (ed. by J. A. Kanis), pp. 89136. Karger, Basel.
15. Kanis, J.A., Powles, T., Paterson, A.H.G., McCloskey, E.V. & Ashley, S. (1996) Clodronate decreases the frequency of skeletal métastases in women with breast cancer. Bone, 19, 663-667.
16. Kaplan. E.L. & Meier, P. (1958) Konparametric estimation from incomplete observations. Journal of American Statisticians Association, 53, 457-481.
17. Klein, B., Zhang, X.G., Lu, Z. & Bataille. R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
18. Kyle, R.A. (1975) Multiple myeloma: review of 869 cases. Mayo Clinic Proceedings, 50, 29.
19. Lahtinen, R., Laakso, M., Palva, I.. Virkkunen. P. & Elomaa, I. (1992) Randomised placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, 340, 1049-1052.
20. MacLennan. I.C., Chapman, C., Dunn, J. & Kelly. K. (1992) Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet, 339, 200-205.
21. McCloskey, E.V., Spector, D., Eyres. K.S., Fern, D.E., O'Rourke, N., Vasikaran, S. & Kanis, J.A. (1993) The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporosis International, 3, 38-147.
22. McElwain, T.J. & Powles, R.L. (1983) High dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet ii, 822-824.
23. Mundy, G.R. (1991) Mechanisms of osteolytic bone destruction. Bone, 12, (Suppl. 1), S1-S6.
24. O'Rourke, N.P., McCloskey, E.V., Vasikaran, S., Eyres, K., Fern, D. & Kanis, J.A. (1993) Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer, 67, 560-563.
25. Paterson. A.H.G., Powles, T.J., Kanis, J.A., McCloskey, E.V., Hanson. J. & Ashley, S. (1993) Double-blind controlled trial of oral clodronate in patients with bone métastases from breast cancer. Journal of Clinical Oncology, 11, 59-65.
26. Peto, R., Pike, M.C., Armitage. P.. Breslow, N.B., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K.. Peto, J. & Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and example. British Journal of Cancer, 35, 1-39.
27. Riccardi, A., Ucci, G., Brugnatelli, S., Mora, 0., Merlini, G., Piva, N., de Paoli, A., Barbarano, L., di Stasi, M., Aberio, F., Nicoletti, G., Morandi, S., Rinaldi. E., Piccinini, L. & Ascari, E. (1994) A prospective, controlled, non-randomised study on prophylactic parenteral dicholoromethylene bisphosphonate (clodronate) in multiple myeloma. International Journal of Oncology. 5, 833-839.
28. Sasaki, A., Boyce, B.F.. Story, B., Wright, K.R., Chapman, M., Boyce, R., Mundy, G.R. & Yoneda, T. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research, 55, 3551-3557.
29. Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers, S., Greaves, M. & Kanis, J.A. (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone résorption. European Journal of Haematologu, 49, 192-198.
30. Valentin-Opran, A., Charhon. S.A., Meunier, P.J., Edouard, M.C. & Arlot, M. (1982) Quantitative histology of myeloma-induced bone changes. British Journal of Haematology, 52, 601-610.
31. Warburton, P., Dunn, J.A. & Maclennan, I.C.M. (1994) Cambridge Medical Reviews: Haematological Oncology, Vol. 3, pp. 95-114. Cambridge University Press.
32. Wimalawansa, S. (1994) Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clinical Endocrinology. 41, 591-595.